Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A five-drug, risk-adapted regimen is changing the game for high-risk multiple myeloma patients. The OPTIMUM trial's 5-year follow-up found that patients on extended therapy were far more likely to be alive and progression-free at 6 years compared to those on conventional treatment. The findings, published in The Lancet Oncology, support broader use of risk-stratified treatment for this hard-to-treat population.
A risk-adapted, five-drug treatment strategy is showing remarkable long-term results for patients with newly diagnosed high-risk multiple myeloma. The OPTIMUM trial's 5-year follow-up — published in The Lancet Oncology — compared 107 patients on an intensified regimen (daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone) with 120 molecularly matched patients who received conventional therapy. The results were striking across the board.
The extended therapy group saw dramatically better outcomes at the 6-year mark, with survival benefits holding up across most molecular subgroups. Notably, patients with plasma cell leukemia — a particularly aggressive form — had more modest results, and those with three or more high-risk cytogenetic abnormalities showed no discernible benefit.
Why it matters: High-risk multiple myeloma has historically been difficult to treat with poor long-term outcomes. These findings make a strong case for risk-stratified treatment and expanded access to molecular diagnostic testing to identify patients who stand to benefit most.
